Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Jaguar Health Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
JAGX
Nasdaq
2834
https://jaguar.health/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Jaguar Health Inc
Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company’s Expanding Focus on Cancer Supportive Care
- Apr 22nd, 2024 12:45 pm
Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care
- Apr 18th, 2024 12:30 pm
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
- Apr 16th, 2024 12:30 pm
Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
- Apr 9th, 2024 8:15 pm
Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement
- Apr 8th, 2024 12:30 pm
Jaguar Health Full Year 2023 Earnings: US$1.79 loss per share (vs US$36.18 loss in FY 2022)
- Apr 3rd, 2024 11:10 am
Jaguar Health, Inc. (NASDAQ:JAGX) Q4 2023 Earnings Call Transcript
- Apr 2nd, 2024 3:24 pm
Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International
- Apr 2nd, 2024 12:50 pm
Q4 2023 Jaguar Health Inc Earnings Call
- Apr 2nd, 2024 6:22 am
Jaguar Health Reports 2023 Financial Results
- Apr 1st, 2024 12:00 pm
Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates
- Mar 27th, 2024 12:30 pm
GEN to Commercialize Jaguar Health's Crofelemer in Turkey and Eight Neighboring Countries and Invest $2 Million in Jaguar Stock at 75% Premium to Market
- Mar 20th, 2024 12:30 pm
Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance
- Feb 23rd, 2024 1:30 pm
Jaguar Health Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
- Feb 15th, 2024 1:30 pm
Jaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct Relief
- Feb 14th, 2024 1:30 pm
Jaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Crofelemer for Cholera-Related Diarrhea
- Feb 12th, 2024 1:30 pm
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Study Indicates Psychoactive Activity of Medicinal Plant Utilized for Centuries by Indigenous Peoples in Tropical Regions
- Jan 30th, 2024 1:45 pm
Jaguar Health to Present January 31 at The Microcap Conference and Participate in a Fireside Chat February 1 at the Lytham Partners Investor Select Conference
- Jan 29th, 2024 1:30 pm
Dog Study Published in PLOS ONE Shows Statistically Significant Results for Use of Jaguar Health’s Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea (CTD)
- Jan 25th, 2024 1:30 pm
Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Jan 5th, 2024 9:15 pm
Scroll